Japan Diagnostic Testing Market Size and Growth Overview (2025-2033)
Market Size in 2024: USD 11.99 Billion
Market Forecast in 2033: USD 19.16 Billion
Market Growth Rate 2025-2033: 4.80%
According to IMARC Group's latest research publication, "Japan Diagnostic Testing Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", the Japan Diagnostic Testing Market size reached USD 11.99 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 19.16 Billion by 2033, exhibiting a growth rate (CAGR) of 4.80% from 2025-2033.
Download a sample PDF of this report: https://www.imarcgroup.com/japan-diagnostic-testing-market/requestsample
How AI is Reshaping the Future of Japan Diagnostic Testing Market?
- Artificial Intelligence (AI) integration enhances diagnostic accuracy, speed, and efficiency, particularly in imaging, pathology, and molecular diagnostics, by analyzing complex data more effectively than traditional methods.
- AI reduces human error in diagnostics, thus improving reliability and patient outcomes.
- The MONCAD CTLN AI-powered lung cancer diagnosis tool, launched via a partnership between Monitor Corporation and Doctor-NET, aids radiologists in detecting lung cancer from CT scans amidst a shortage of radiologists.
- AI-driven diagnostics contribute to personalized medicine by analyzing genetic data and recommending tailored treatment plans.
- Growing investment in AI technologies is making healthcare delivery more proactive and precise, helping manage diseases more efficiently in Japan.
- AI's transformative impact extends to faster and more reliable interpretation of results, enhancing the overall clinical workflow and reducing healthcare system burdens.
Market Growth Factors
Another driving force for the Japan diagnostic testing market is point-of-care (POC) testing, which offers rapid and convenient results in the immediate vicinity of the patient. Emergency rooms, clinics, and home care are the most common types of POC sites. An aging population and an emphasis on screening have also contributed to demand. The first point-of-care (POC) system in the world that detects antimicrobial susceptibility after 30 minutes for UTI was introduced by Sysmex Corporation using its new microfluidic technology. The technology will help to tackle antimicrobial resistance (AMR), hospital congestion, and encourage optimum use of healthcare resources globally.
AI is being used to advance diagnostic testing in Japan, increasing detection accuracy, reducing diagnostic errors, and improving analytical efficiency and speed: detecting subtle patterns and abnormalities in imaging and molecular diagnostics that exceed human capability. AI tools, such as Monitor Corporation's MONCAD CTLN, assist radiologists in the early detection of lung cancer on CT scans. This may help lessen the lack of radiologists. AI analytics also interprets genetic information. This use creates customized treatment options for personalized medicine. Healthcare delivery becomes more effective. AI-based diagnostic solutions experience increased demand.
Collaborations and partnerships for developing new diagnostic solutions have been actively established in Japan. For example, in August 2024, Hitachi High-Tech announced it had partnered with Gencurix in order to advance cancer molecular diagnostics with diagnostic solutions and discover biomarkers for personalized medicine. C2N Diagnostics, with Mediford Corporation, partnered so they could develop a blood-based diagnostic that detects Alzheimer's disease in April 2024. They worked together to grow their shared aim to find early and handle nerve problems, showing the growing move to make biomarker tech markets digital in test tools.
Market Segmentation
Test Type Insights:
- Laboratory Testing
- Point-of-Care Testing (POCT)
- Imaging Diagnostics
- Molecular Diagnostics
- Others
Technology Insights:
- Immunoassay-Based
- PCR-Based
- Next Gen Sequencing
- Spectroscopy-Based
- Chromatography-Based
- Microfluidics
- Others
Sample Type Insights:
- Blood
- Urine
- Saliva
- Sweat
- Hair
- Others
Mode of Testing Insights:
- Prescription-Based Testing
- OTC Testing
Application Insights:
- Oncology
- Cardiology
- Orthopedics
- Gastroenterology
- Gynecology
- Neurology
- Odontology
- Others
End User Insights:
- Hospitals
- Diagnostic Centers
- Ambulatory Surgical Centers (ASCs)
- Specialty Clinics
- Homecare
- Blood Banks
- Research Labs and Institutes
- Others
Regional Insights:
- Kanto Region
- Kansai/Kinki Region
- Central/Chubu Region
- Kyushu-Okinawa Region
- Tohoku Region
- Chugoku Region
- Hokkaido Region
- Shikoku Region
Request a Customized Version of This Report for Deeper Insights: https://www.imarcgroup.com/request?type=report&id=35217&flag=E
Recent Development & News
- In August 2024, Hitachi High-Tech and Gencurix announced their partnership to enhance cancer molecular diagnostics, combining Hitachi's expertise in diagnostic products with Gencurix's biomarker discovery technology. Their collaboration aims to develop reliable testing services in Japan, promoting personalized medicine and improving cancer diagnosis through advanced digital solutions and innovative testing methodologies.
- In April 2024, C2N Diagnostics announced its partnership with Mediford Corporation to expand its Alzheimer’s disease blood testing services in Japan. This collaboration enhances access to advanced biomarker testing, addressing the country’s high prevalence of Alzheimer’s. C2N aims to support clinical research and improve early diagnosis and treatment monitoring for neurological diseases in Japan.
Customization Note:
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
Street: 563-13 Kamien
Area: Iwata
Country: Tokyo, Japan
Postal Code: 4380111
Email: sales@imarcgroup.com
